⁃ Patients of all genders, age \>18 years

⁃ Participant is willing and able to give informed consent for participation in the study.

⁃ Evidence of cirrhosis CP A or B (as defined below, cirrhosis ever diagnosed), with an underlying aetiology of at least one of the following: chronic Hepatitis B Virus (HBV) infection, chronic Hepatitis C Virus (HCV) infection, alcoholic liver disease, non-alcoholic fatty liver disease or haemochromatosis

‣ Cirrhosis Diagnosis Definition

⁃ Histological assessment (Ishak stage 5 or 6) or

⁃ At least one of the following:

‣ i. Validated non-invasive marker of fibrosis including fibroscan, AST to Platelet Ratio Index (APRI) score \>2 or Enhanced Liver Fibrosis (ELF) score \>10.48 or Fibrotest score \>0.73. Fibroscan readings should be assessed by aetiology as below:

• HBV: \>=10 kPa

• HCV: \>=14.5 kPa

• Alcoholic Liver Disease (ALD): \>=19.5 kPa

• Non-alcoholic fatty liver disease (NAFLD): \>=15 kPa

• Haemochromatosis: \>=12kPa ii. Evidence of varices at endoscopy or imaging in the context of a patent portal vein iii. Definitive radiological evidence of cirrhosis (i.e. nodularity of liver and splenomegaly on Ultrasound/CT)